Ernexa Therapeutics (ERNA)
Develops off-the-shelf engineered iMSC therapies for cancer and autoimmune disease.
Something off on this page? Send us feedback.
Develops off-the-shelf engineered iMSC therapies for cancer and autoimmune disease, with ERNA-101 in ovarian cancer and ERNA-201 in inflammatory disease; it has no approved products or operating revenue.
Develops synthetic, allogeneic iMSC therapies by engineering induced pluripotent stem cells, differentiating them into iMSCs, and programming them to deliver immune-modulating cytokines. ERNA-101 targets platinum-resistant ovarian cancer through an IL-7/IL-15 fusion cytokine, while ERNA-201 targets autoimmune and inflammatory disease by secreting IL-10.
Pursues standardized, off-the-shelf supply without patient-specific cell harvesting and seeks strategic partners, out-licensing, and research grants alongside product development. The pipeline remains preclinical, with no approved product or revenue-generating customer contract; its technology rights come from Factor Limited and manufacturing execution relies on Cellipont Bioservices and other contract manufacturers.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $5.0M · Total debt $349.0K · Total assets $6.3M · Shareholders' equity $3.2M
- Revenue
- $0
- Operating income
- −$4.1M
- Net income
- −$4.0M
No dividends on record.
| Institutions19 holders · as of Mar 31, 2026 | 8.76% | 143.0K shares | |
| Insiders3 holders · as of Aug 27, 2026 | 17.10% | 279.2K shares | |
| Otherremainder | 74.14% | 1.21M shares |
1.63M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (1.63M in the company's Sep 3, 2026 report, 314.1K elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Charles CheringtonInsider10 percent owner | 16.61% | 271,178 | Form 4filed Feb 17, 2026 ↗ |
Bleichroeder LPInstitution | 4.90% | 2.00M | 13Fas of Mar 31, 2026 |
Dauntless Investment Group, LLCInstitution | 1.50% | 612,443 | 13Fas of Mar 31, 2026 |
Ci Private Wealth, LLCInstitution | 1.07% | 438,093 | 13Fas of Mar 31, 2026 |
Geode Capital Management, LLCInstitution | 0.60% | 244,446 | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings · Form 4 — an insider's transaction report
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Feb 10, 2026 | Charles Cherington | 10 percent owner | +8,000,000 | $0.5900 |
- Fate
iPSC-derived off-the-shelf therapies for cancer and autoimmunity.
- Century Therapeutics
Allogeneic iPSC therapies spanning cancer and autoimmune disease.
- Mesoblast (ADR)
MSC platform benchmark with approved allogeneic cell therapy.
- Calidi Biotherapeutics
Allogeneic stem-cell delivery platforms for solid tumors.
- Allogene Therapeutics
Off-the-shelf cell therapies across cancer and autoimmune disease.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Ernexa Therapeutics | $4.54 | +1.00% | $1.4M | — | — | — | — |
| Fate | $2.49 | +1.67% | $285.6M | — | — | 44.0 | +9.2% |
| Century Therapeutics | $2.12 | −0.24% | $182.7M | — | — | — | — |
| Mesoblast (ADR) | $17.14 | −0.81% | $2.24B | — | — | 33.9 | +882.8% |
| Calidi Biotherapeutics | $1.33 | −2.21% | $617.0K | — | — | — | — |
| Allogene Therapeutics | $1.99 | +0.42% | $683.4M | — | — | 147.3 | — |
| Median | — | — | 44.0 | +446.0% |